Nurix Therapeutics, Inc. (NRIX) income statement
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.24−0.49 (-3.33%)
Close on Nov 17, 2026Market cap $1.56BP/E 6.2Yield 0.00%
Nurix Therapeutics, Inc. income statement
Ratios
Latest available, balances at Aug 31, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- 41.3%
- Net margin
- 42.0%
- Return on equity, FY2025
- -49.6%
Financial strength
- Current ratio
- 8.44
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 550.9%
Valuation
- P/E ratio
- 6.2
- Price to sales
- 2.22
- Price to book
- 1.61
- Dividend yield
- 0.00%
See a number that looks wrong?